Free  Sagas

Marketing Authorisations

Esketamine (Spravato°) in depression after failure of several antidepressants or with a high risk of suicide

Dabrafenib (Finlee°) + trametinib (Spexotras°) in certain gliomas with a BRAF V600E mutation

Cemiplimab (Libtayo°) + chemotherapy as first-line treatment in metastatic or inoperable lung cancer

Fexinidazole (Fexinidazole Winthrop°) in sleeping sickness caused by Trypanosoma brucei rhodesiense

Editors' opinion. Exception to the rule

Nivolumab (Opdivo°) after resection of melanoma without lymph node involvement, but at high risk of recurrence

20-valent pneumococcal conjugate vaccine (Prevenar 20°) in children and adolescents

Empagliflozin (Jardiance°) in chronic kidney disease

Posaconazole (Noxafil°) in invasive fungal infections from 2 years of age

Metamizole: European marketing authorisations maintained despite the risk of fatal agranulocytosis

Thiocolchicoside is genotoxic and teratogenic: continue to use contraception after treatment cessation

Free  Prescrire's ratings of new drugs in 2024: a brief review

Adverse Effects

SSRI antidepressants and venlafaxine: increased risk of injuries

Nitrates + sildenafil, tadalafil or vardenafil: risk of cardiovascular death

Semaglutide: optic neuropathy

Proton pump inhibitors: hyponatraemia, especially at the start of treatment

Antiarrhythmic drugs in atrial fibrillation: pacemaker implantation and syncope

VEGF inhibitors: aortic dissection

Common stem: -zepine

Outlook

Opioid crisis in the US: advertising agency's alleged role

Perindopril: Servier sanctioned for breach of antitrust rules

Artificial intelligence: critical thinking is lacking

Masthead

Free  Masthead